Publications

Kauffman EC, Robinson BD, Downes M, Marcinkiewicz K, Vourganti S, Scherr DS, Gudas LJ, Mongan NP.  2013.  Estrogen receptor-β expression and pharmacological targeting in bladder cancer.. Oncol Rep. 30(1):131-8.

Harris AE, Metzler VM, Lothion-Roy J, Varun D, Woodcock CL, Haigh DB, Endeley C, Haque M, Toss MS, Alsaleem M et al..  2022.  Exploring anti-androgen therapies in hormone dependent prostate cancer and new therapeutic routes for castration resistant prostate cancer.. Front Endocrinol (Lausanne). 13:1006101.

Harris AE, Metzler VM, Lothion-Roy J, Varun D, Woodcock CL, Haigh DB, Endeley C, Haque M, Toss MS, Alsaleem M et al..  2022.  Exploring anti-androgen therapies in hormone dependent prostate cancer and new therapeutic routes for castration resistant prostate cancer.. Front Endocrinol (Lausanne). 13:1006101.

Harris AE, Metzler VM, Lothion-Roy J, Varun D, Woodcock CL, Haigh DB, Endeley C, Haque M, Toss MS, Alsaleem M et al..  2022.  Exploring anti-androgen therapies in hormone dependent prostate cancer and new therapeutic routes for castration resistant prostate cancer.. Front Endocrinol (Lausanne). 13:1006101.

Harris AE, Metzler VM, Lothion-Roy J, Varun D, Woodcock CL, Haigh DB, Endeley C, Haque M, Toss MS, Alsaleem M et al..  2022.  Exploring anti-androgen therapies in hormone dependent prostate cancer and new therapeutic routes for castration resistant prostate cancer.. Front Endocrinol (Lausanne). 13:1006101.

Harris AE, Metzler VM, Lothion-Roy J, Varun D, Woodcock CL, Haigh DB, Endeley C, Haque M, Toss MS, Alsaleem M et al..  2022.  Exploring anti-androgen therapies in hormone dependent prostate cancer and new therapeutic routes for castration resistant prostate cancer.. Front Endocrinol (Lausanne). 13:1006101.

Kopparapu PKumar, Boorjian SA, Robinson BD, Downes M, Gudas LJ, Mongan NP, Persson JL.  2013.  Expression of cyclin d1 and its association with disease characteristics in bladder cancer.. Anticancer Res. 33(12):5235-42.

Kopparapu PKumar, Boorjian SA, Robinson BD, Downes M, Gudas LJ, Mongan NP, Persson JL.  2013.  Expression of VEGF and its receptors VEGFR1/VEGFR2 is associated with invasiveness of bladder cancer.. Anticancer Res. 33(6):2381-90.

Tang X-H, Marta M, Gudas LJ, Mai K, Trasino SE.  2021.  Fenretinide Improves Intestinal Barrier Function and Mitigates Alcohol Liver Disease. Front. Pharmacol.

Tang X-H, Marta M, Gudas LJ, Mai K, Trasino SE.  2021.  Fenretinide Improves Intestinal Barrier Function and Mitigates Alcohol Liver Disease. Front. Pharmacol.

Melis M, Tang X-H, Mai K, Gudas LJ, Trasino SE.  2022.  Fenretinide Reduces Intestinal Mucin-2-Positive Goblet Cells in Chronic Alcohol Abuse.. Pharmacology. :1-11.

Melis M, Tang X-H, Mai K, Gudas LJ, Trasino SE.  2022.  Fenretinide Reduces Intestinal Mucin-2-Positive Goblet Cells in Chronic Alcohol Abuse.. Pharmacology. :1-11.

Fu L, Minton DR, Zhang T, Nanus DM, Gudas LJ.  2015.  Genome-Wide Profiling of TRACK Kidneys Shows Similarity to the Human ccRCC Transcriptome.. Mol Cancer Res. 13(5):870-8.

van der Mijn JC, Eng KW, Chandra P, Fernandez E, Ramazanoglu S, Sigaras A, Oromendia C, Gudas LJ, Tagawa ST, Nanus DM et al..  2022.  The genomic landscape of metastatic clear cell renal cell carcinoma after systemic therapy.. Mol Oncol.

van der Mijn JC, Eng KW, Chandra P, Fernandez E, Ramazanoglu S, Sigaras A, Oromendia C, Gudas LJ, Tagawa ST, Nanus DM et al..  2022.  The genomic landscape of metastatic clear cell renal cell carcinoma after systemic therapy.. Mol Oncol.

Martinez-Ceballos E, Gudas LJ.  2008.  Hoxa1 is required for the retinoic acid-induced differentiation of embryonic stem cells into neurons.. J Neurosci Res. 86(13):2809-19.

Raman JD, Mongan NP, Tickoo SK, Boorjian SA, Scherr DS, Gudas LJ.  2005.  Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder.. Clin Cancer Res. 11(24 Pt 1):8570-6.

Orfali N, O'Donovan TR, Nyhan MJ, Britschgi A, Tschan MP, Cahill MR, Mongan NP, Gudas LJ, McKenna SL.  2015.  Induction of autophagy is a key component of all-trans-retinoic acid-induced differentiation in leukemia cells and a potential target for pharmacologic modulation.. Exp Hematol. 43(9):781-93.e2.

Orfali N, O'Donovan TR, Nyhan MJ, Britschgi A, Tschan MP, Cahill MR, Mongan NP, Gudas LJ, McKenna SL.  2015.  Induction of autophagy is a key component of all-trans-retinoic acid-induced differentiation in leukemia cells and a potential target for pharmacologic modulation.. Exp Hematol. 43(9):781-93.e2.

Orfali N, Shan-Krauer D, O'Donovan TR, Mongan NP, Gudas LJ, Cahill MR, Tschan MP, McKenna SL.  2019.  Inhibition of UBE2L6 attenuates ISGylation and impedes ATRA-induced differentiation of leukemic cells.. Mol Oncol.

Orfali N, Shan-Krauer D, O'Donovan TR, Mongan NP, Gudas LJ, Cahill MR, Tschan MP, McKenna SL.  2019.  Inhibition of UBE2L6 attenuates ISGylation and impedes ATRA-induced differentiation of leukemic cells.. Mol Oncol.

Metzler VM, de Brot S, Haigh DB, Woodcock CL, Lothion-Roy J, Harris AE, Nilsson EM, Ntekim A, Persson JL, Robinson BD et al..  2023.  The KDM5B and KDM1A lysine demethylases cooperate in regulating androgen receptor expression and signalling in prostate cancer.. Front Cell Dev Biol. 11:1116424.

Metzler VM, de Brot S, Haigh DB, Woodcock CL, Lothion-Roy J, Harris AE, Nilsson EM, Ntekim A, Persson JL, Robinson BD et al..  2023.  The KDM5B and KDM1A lysine demethylases cooperate in regulating androgen receptor expression and signalling in prostate cancer.. Front Cell Dev Biol. 11:1116424.

Metzler VM, de Brot S, Haigh DB, Woodcock CL, Lothion-Roy J, Harris AE, Nilsson EM, Ntekim A, Persson JL, Robinson BD et al..  2023.  The KDM5B and KDM1A lysine demethylases cooperate in regulating androgen receptor expression and signalling in prostate cancer.. Front Cell Dev Biol. 11:1116424.

Williams RM, Shah J, Mercer E, Tian HS, Thompson V, Cheung JM, Dorso M, Kubala JM, Gudas LJ, de Stanchina E et al..  2021.  Kidney-Targeted Redox Scavenger Therapy Prevents Cisplatin-Induced Acute Kidney Injury.. Front Pharmacol. 12:790913.